The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
A phase 3 trial of FAP-2286, Enzalutamide, Abiraterone acetate in prostate cancer, run by Telix Pharmaceuticals (Innovations) Pty Limited, now recruiting.
Overview
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) is a phase 3 interventional study registered as NCT06520345 by Telix Pharmaceuticals (Innovations) Pty Limited, with 520 participants planned, started 2024-07-26 and due to reach its primary completion in 2027-12. Interventions recorded: 177Lu-TLX591, Enzalutamide, Abiraterone, Docetaxel. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA
Shares Abiraterone acetate, Enzalutamide, Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialAnti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Shares FAP-2286 (177Lu / 68Ga), Metastatic castration-resistant prostate cancer, Prostate cancer, Lutetium-177.
- TrialAn Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
Shares FAP-2286 (177Lu / 68Ga), Metastatic castration-resistant prostate cancer, Prostate cancer, Lutetium-177.
- TrialAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Shares Abiraterone acetate, Enzalutamide, Metastatic castration-resistant prostate cancer, Prostate cancer.
- PathwayProstate cancer (KEGG map)
Shares Abiraterone acetate, Enzalutamide, Prostate cancer, Lutetium-177.
- TrialSTAMPEDE
Shares Docetaxel, Abiraterone acetate, Enzalutamide, Prostate cancer.
- IndicationMetastatic hormone-sensitive prostate cancer
Shares Docetaxel, Abiraterone acetate, Enzalutamide, Metastatic castration-resistant prostate cancer.
- CollectionProstate Cancer Foundation (PCF)
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.